Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-39.09 Mln
EBITDA
$-56.07 Mln
Net Profit
$-65.93 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bone Biologics Corp Warrants (BBLGW)
| -49.50 | -2.88 | -27.34 | -0.74 | 266.60 | -- | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Bone Biologics Corp Warrants (BBLGW)
| 901.27 | 21,677.78 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific... control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Address: 2 Burlington Woods Drive, Burlington, MA, United States, 01803 Read more
CEO & President
Mr. Jeffrey Frelick
CEO & President
Mr. Jeffrey Frelick
Headquarters
Burlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bone Biologics Corp Warrants (BBLGW) is $20.20 (NASDAQ) as of 25-Mar-2025 09:30 EDT. Bone Biologics Corp Warrants (BBLGW) has given a return of 266.6% in the last 3 years.
Bone Biologics Corp Warrants (BBLGW) has a market capitalisation of -- as on 25-Mar-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bone Biologics Corp Warrants (BBLGW) and enter the required number of quantities and click on buy to purchase the shares of Bone Biologics Corp Warrants (BBLGW).
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration. It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company's NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Address: 2 Burlington Woods Drive, Burlington, MA, United States, 01803
The CEO & director of Mr. Jeffrey Frelick. is Bone Biologics Corp Warrants (BBLGW), and CFO & Sr. VP is Mr. Jeffrey Frelick.
There is no promoter pledging in Bone Biologics Corp Warrants (BBLGW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Bone Biologics Corp Warrants (BBLGW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bone Biologics Corp Warrants (BBLGW) was $0 Mln.
